CTPI-2 | CAS# 68003-38-3 | SLC25A1 Inhibitor

MedKoo Cat#: 565231 | Name: CTPI-2

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CTPI-2, also known as ABD7, is a specific SLC25A1 inhibitor.

Chemical Structure

CTPI-2

CAS#68003-38-3

Theoretical Analysis

MedKoo Cat#: 565231

Name: CTPI-2

CAS#: 68003-38-3

Chemical Formula: C13H9ClN2O6S

Exact Mass: 355.9870

Molecular Weight: 356.73

Elemental Analysis: C, 43.77; H, 2.54; Cl, 9.94; N, 7.85; O, 26.91; S, 8.99

Price and Availability

Size	Price	Availability
10mg	USD 90.00	Ready to ship
25mg	USD 150.00	Ready to ship
50mg	USD 250.00	Ready to ship
100mg	USD 450.00	Ready to ship
200mg	USD 750.00	Ready to ship
500mg	USD 1,450.00	Ready to ship
1g	USD 2,450.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

68003-38-3

Synonym

ABD-7; ABD 7; ABD7; RAS inhibitor Abd-7; CTPI-2; CTPI 2; CTPI2; D1W

IUPAC/Chemical Name

2-(4-Chloro-3-nitrobenzenesulfonamido)benzoic acid

InChi Key

NJTHPOSQGFJTDP-UHFFFAOYSA-N

InChi Code

InChI=1S/C13H9ClN2O6S/c14-10-6-5-8(7-12(10)16(19)20)23(21,22)15-11-4-2-1-3-9(11)13(17)18/h1-7,15H,(H,17,18)

SMILES Code

O=C(O)C1=CC=CC=C1NS(=O)(C2=CC=C(Cl)C([N+]([O-])=O)=C2)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot# A22T05K25

QC Data

View QC data: current batch, Lot# A22T05K25

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

CTPI-2 is a third-generation mitochondrial citrate carrier SLC25A1 inhibitor with a KD of 3.5 μM. CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4.

In vitro activity:

CTPI-2 inhibited mitochondrial respiration of CSCs spheres (Fig. 4c) and effectively inhibited their self-renewal again showing lesser anti-proliferative activity in 2D cultures (Figs. 5a–c). Reference: Cell Death Differ. 2018 Jul;25(7):1239-1258. https://pubmed.ncbi.nlm.nih.gov/29651165/

In vivo activity:

This study next studied the effects of CTPI-2 in the liver of HFD-fed mice. In mice fed with the HFD the liver was filled with fatty deposits that accumulated over time in the form of micro- and macrovesicular steatosis, and the hepatocytes exhibited typical ballooning degeneration, indicating the presence of steatohepatitis (Fig. 2a). Accordingly, these mice displayed hypercholesterolemia and hepatic injury as demonstrated by the elevated levels of Alanine Aminotransferase (ALT) and CTPI-2 normalized cholesterol, ALT and triglyceride levels (Fig. 2b–d). After 3 months of exposure to the HFD, at which time CTPI-2 treatment started, steatosis was already evident and progressed over time. CTPI-2 reverted these early stages of steatosis and also prevented the evolution to steatohepatitis, identified based upon the dramatic increase of lipid accumulation, the presence of hepatocyte ballooning (Fig. 2a), the elevated levels of ALT (Fig. 2c) and the presence of perivascular inflammatory infiltration (not shown). Reference: Cell Death Differ. 2020 Jul;27(7):2143-2157. https://pubmed.ncbi.nlm.nih.gov/31959914/

	Solvent	mg/mL	mM
Solubility
	DMSO	160.5	449.92
	Ethanol	71.0	199.03

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 356.73 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Fernandez HR, Gadre SM, Tan M, Graham GT, Mosaoa R, Ongkeko MS, Kim KA, Riggins RB, Parasido E, Petrini I, Pacini S, Cheema A, Varghese R, Ressom HW, Zhang Y, Albanese C, Üren A, Paige M, Giaccone G, Avantaggiati ML. The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. Cell Death Differ. 2018 Jul;25(7):1239-1258. doi: 10.1038/s41418-018-0101-z. Epub 2018 Apr 12. PMID: 29651165; PMCID: PMC6030199. 2. Tan M, Mosaoa R, Graham GT, Kasprzyk-Pawelec A, Gadre S, Parasido E, Catalina-Rodriguez O, Foley P, Giaccone G, Cheema A, Kallakury B, Albanese C, Yi C, Avantaggiati ML. Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH. Cell Death Differ. 2020 Jul;27(7):2143-2157. doi: 10.1038/s41418-020-0491-6. Epub 2020 Jan 20. PMID: 31959914; PMCID: PMC7308387.

In vitro protocol:

In vivo protocol:

1. Tan M, Mosaoa R, Graham GT, Kasprzyk-Pawelec A, Gadre S, Parasido E, Catalina-Rodriguez O, Foley P, Giaccone G, Cheema A, Kallakury B, Albanese C, Yi C, Avantaggiati ML. Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH. Cell Death Differ. 2020 Jul;27(7):2143-2157. doi: 10.1038/s41418-020-0491-6. Epub 2020 Jan 20. PMID: 31959914; PMCID: PMC7308387.

1: O'Bryan JP. Pharmacological targeting of RAS: Recent success with direct inhibitors. Pharmacol Res. 2019 Jan;139:503-511. doi: 10.1016/j.phrs.2018.10.021. Epub 2018 Oct 23. Review. PubMed PMID: 30366101; PubMed Central PMCID: PMC6360110.